Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection

尽管每年都在努力接种疫苗，甲型流感病毒（IAV）仍然是一个全球卫生问题。临床干预措施

Influenza A virus (IAV) remains a global health concern despite annual vaccination efforts. Clinical interventions able to prevent the immunopathology and `cytokine storm' associated with severe IAV infection are urgently needed, especially approaches that can be initiated at later stages of infection. The knowledge gained from the proposed studies will facilitate the development of a novel application of an IL-2-based therapeutic approach to treat severe respiratory viral infection, as well as advance its potential use as an adjuvant to boost universal, IAV-specific immunity following vaccination.